Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:ATCCode |
gptkb:N07XX02
|
| gptkbp:bioavailability |
60%
|
| gptkbp:CASNumber |
gptkb:1744-22-5
|
| gptkbp:drugClass |
neuroprotective agent
|
| gptkbp:halfLife |
12 hours
|
| gptkbp:hasEliminationRoute |
renal
fecal |
| gptkbp:hasInChIKey |
YHLBAJQWDFZVBI-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
gptkb:C8H5F3N2OS
|
| gptkbp:hasSMILES |
FC(F)(F)Oc1ccc2nc(sc2c1)N
|
| gptkbp:hasUNII |
7LJ087RS6F
|
| https://www.w3.org/2000/01/rdf-schema#label |
CHEMBL12313
|
| gptkbp:indication |
amyotrophic lateral sclerosis
|
| gptkbp:isApprovedDrug |
true
|
| gptkbp:marketedIn |
gptkb:European_Union
gptkb:United_States |
| gptkbp:mechanismOfAction |
glutamate release inhibitor
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:molecularWeight |
234.2
|
| gptkbp:name |
Riluzole
|
| gptkbp:PubChem_CID |
gptkb:DB00740
5070 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
gptkb:Rilutek
2-Amino-6-(trifluoromethoxy)benzothiazole |
| gptkbp:target |
gptkb:voltage-gated_potassium_channel
gptkb:glutamate_receptor |
| gptkbp:bfsParent |
gptkb:ibogaine
|
| gptkbp:bfsLayer |
6
|